Pelubiprofen - CAS 69956-77-0
Catalog: |
BB034025 |
Product Name: |
Pelubiprofen |
CAS: |
69956-77-0 |
Synonyms: |
(E)-2-[4-[(2-Oxocyclohexylidene)methyl]phenyl]propanoic Acid; (±)-p-[[(E)-2-Oxocyclohexylidene]methyl]hydratropic Acid; Benzeneacetic acid, α-methyl-4-[(E)-(2-oxocyclohexylidene)methyl]-; α-Methyl-4-[((E)-2-oxocyclohexylidene)methyl]benzeneacetic acid |
IUPAC Name: | 2-[4-[(E)-(2-oxocyclohexylidene)methyl]phenyl]propanoic acid |
Description: | Pelubiprofen, a member of the 2-arylpropionic acid family, is an orally active, non-steroidal anti-inflammatory and analgesic agent that has a relatively selective effect on COX-2 activity. It inhibits COX activity and TGF-β-activated kinase 1-IκB kinase β-NF-κB pathway. |
Molecular Weight: | 258.31 |
Molecular Formula: | C16H18O3 |
Canonical SMILES: | CC(C1=CC=C(C=C1)C=C2CCCCC2=O)C(=O)O |
InChI: | InChI=1S/C16H18O3/c1-11(16(18)19)13-8-6-12(7-9-13)10-14-4-2-3-5-15(14)17/h6-11H,2-5H2,1H3,(H,18,19)/b14-10+ |
InChI Key: | AUZUGWXLBGZUPP-GXDHUFHOSA-N |
Boiling Point: | 457.4±34.0°C (Predicted) |
Purity: | ≥95% |
Density: | 1.199±0.06 g/cm3 (Predicted) |
LogP: | 3.40120 |
Publication Number | Title | Priority Date |
CN-113149826-A | Preparation process of pelubiprofen | 20210408 |
WO-2021209892-A1 | Pharmaceutical composition comprising benzimidazole derivative compound | 20200413 |
CN-111039782-A | Crystal form of 2- [4- [ (E) - (2-ketocyclohexenyl) methyl ] phenyl ] propionic acid and preparation method thereof | 20191226 |
CN-111153791-A | Preparation method of pelubiprofen with different particle sizes | 20191226 |
WO-2021129651-A1 | 2-[4-[(e)-(2-ketocyclohexenyl)methyl]phenyl]propionic acid crystal form and preparation method therefor | 20191226 |
PMID | Publication Date | Title | Journal |
32020584 | 20200501 | The IUPHAR Guide to Immunopharmacology: connecting immunology and pharmacology | Immunology |
25403311 | 20141118 | Comparison of the efficacy and safety profiles of a pelubiprofen versus celecoxib in patients with rheumatoid arthritis: a 6-week, multicenter, randomized, double-blind, phase III, non-inferiority clinical trial | BMC musculoskeletal disorders |
21809372 | 20111201 | Anti-inflammatory effect of pelubiprofen, 2-[4-(oxocyclohexylidenemethyl)-phenyl]propionic acid, mediated by dual suppression of COX activity and LPS-induced inflammatory gene expression via NF-κB inactivation | Journal of cellular biochemistry |
18274955 | 20080301 | Leukotriene B4 12-hydroxydehydrogenase/15-ketoprostaglandin Delta 13-reductase (LTB4 12-HD/PGR) responsible for the reduction of a double-bond of the alpha,beta-unsaturated ketone of an aryl propionic acid non-steroidal anti-inflammatory agent CS-670 | Xenobiotica; the fate of foreign compounds in biological systems |
8857182 | 19960101 | Disposition of CS-670, a novel nonsteroidal anit-inflammatory drug, and its metabolites in healthy human volunteers | Chirality |
Complexity: | 376 |
Compound Is Canonicalized: | Yes |
Covalently-Bonded Unit Count: | 1 |
Defined Atom Stereocenter Count: | 0 |
Defined Bond Stereocenter Count: | 1 |
Exact Mass: | 258.125594432 |
Formal Charge: | 0 |
Heavy Atom Count: | 19 |
Hydrogen Bond Acceptor Count: | 3 |
Hydrogen Bond Donor Count: | 1 |
Isotope Atom Count: | 0 |
Monoisotopic Mass: | 258.125594432 |
Rotatable Bond Count: | 3 |
Topological Polar Surface Area: | 54.4 |
Undefined Atom Stereocenter Count: | 1 |
Undefined Bond Stereocenter Count: | 0 |
XLogP3: | 3 |
Online Inquiry
Customer Support
Customer Centered
Related Functional Groups
Carbonyl Compounds
Customers Also Viewed
-
[61078-14-6]
1-Methyl-2-(methylsulfonyl)benzimidazole
-
[888711-44-2]
Potassium (Bromomethyl)trifluoroborate
-
[80935-77-9]
2,6-Naphthyridin-1(2H)-one
-
[853029-57-9]
8-bromo-7-(but-2-yn-1-yl)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-3,7-dihydro-1H-purine-2,6-dione
-
[1388152-02-0]
1,2-Cyclopentanediol, 3-amino-5-[(phosphonooxy)methy]-, ammonium salt (1:2), (1R,2S,3R,5R)-
-
[6982-39-4]
trans-2-Aminocyclohexanol
INDUSTRY LEADERS TRUST OUR PRODUCTS